A 10-person startup called Marea said Tuesday that it had raised $190 million to help develop a drug to lower a type of cholesterol — what scientists call “remnant cholesterol” — that could represent a new way of attacking cardiovascular disease.
The story of that drug, the protein that it targets, and the gene that codes for that protein (both are called ANGPTL4) says a lot about why medicines are so tough to develop and why heart disease remains the biggest killer in the U.S., taking 700,000 lives every year. It also offers a freeze-frame photo of the way in which the biotech industry’s capitalist flywheel of boom and bust cycles provides glimmers of scientific hope.
Marea, which is about three years old, is still at the beginning of its scientific journey. Its drug, initially developed at Novartis and then licensed to the startup, is only about to enter Phase 2 trials. For heart drugs, real proof of efficacy can require large Phase 3 trials. ANGPTL4, in particular, has a history that stretches back a quarter century — and was explored by several major drugmakers but, apparently, abandoned, because of a worry about side effects in mice.
Click this link for the original source of this article.
Author: Matthew Herper
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.